NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE

Proposed Health Technology Appraisal

Cinacalcet HCI for the treatment of hyperparathyroidism secondary to impaired renal function

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors• Amgen LtdPatient/carer groups• British Kidney Patient Association• British Thyroid Foundation• Kidney Alliance• Long Term Medical Conditions Alliance• National Kidney Federation• Welsh Kidney Patients AssociationProfessional groups• Association of Renal Industries• Association of Renal Technologists• British Dietetic Association• British Renal Society• British Thyroid Association• National Kidney Research Fund• Renal Pharmacy Group• Royal College of Nursing• Royal College of Pathologists• Royal College of Physicians• Royal Pharmaceutical Society• Society for DGH Nephrologists• Welsh Association of Renal Physicians• North Eastern Derbyshire PCT• Welsh Assembly Government	General • Board of Community Health Councils in Wales • National Public Health Service for Wales • NHS Confederation • NHS Purchasing and Supplies Agency • NHS Purchasing and Supplies Agency • NHS Quality Improvement Scotland • British National Formulary Comparator manufacturers • none Relevant research groups • none Assessment team • Peninsula Technology Assessment Group (PenTAG) • National Coordinating Centre for Health Technology Assessment

National Institute for Clinical Excellence

Consultation on the draft remit and draft scope for the proposed appraisal of cinacalcet HCl for the treatment of hyperparathyroidism secondary to impaired renal function Issue date: September 2004